Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 3/20 | 0.50 |
| ▸ | S100A4 | P26447 | 2/20 | 0.50 |
| ▸ | TDP2 | O95551 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22898465 | 0.86 | ACHE (0.52) | PTPRCS100A4TDP2MEN1MAPT | |
| SCHEMBL987760 | 0.74 | TLR9 (0.79) | PTPRCS100A4TDP2MEN1MAPT | |
| SCHEMBL30049268 | 0.74 | TLR9 (0.79) | PTPRCS100A4TDP2MEN1MAPT | |
| SCHEMBL3624177 | 0.72 | KCNJ1 (0.60) | PTPRCS100A4TDP2MEN1MAPT | |
| SCHEMBL1567844 | 0.71 | PTPRC (0.53) | PTPRCS100A4TDP2MEN1MAPT | |
| SCHEMBL6370751 | 0.71 | ACHE (0.53) | PTPRCS100A4TDP2MEN1MAPT | |
| SCHEMBL8762150 | 0.71 | PNMT (0.50) | TDP2MEN1MAPTKMT2ALMNA | |
| SCHEMBL5035485 | 0.70 | ALDH1A1 (0.51) | PTPRCS100A4TDP2MEN1MAPT | |
| SCHEMBL1163250 | 0.69 | TDP2 (0.62) | PTPRCS100A4TDP2MEN1MAPT | |
| SCHEMBL9641625 | 0.69 | TDP2 (0.46) | PTPRCS100A4TDP2MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050277630-A1 | Antibacterial agents | CHUPAK LOUIS S | 2005-12-15 | — | — | US | disclosed |
| EP-1594495-A1 | OXAZOLIDINONE DERIVATES N-SUBSTITUTED BY A TRICYCLIC RING, FOR USE AS ANTIBACTERIAL AGENTS | Warner-Lambert Company LLC (US) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004069245-A1 | OXAZOLIDINONE DERIVATES N-SUBSTITUTED BY A TRICYCLIC RING, FOR USE AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277630-A1 | Antibacterial agents | MRPL21, RPN2, FBL | PTPRC 3751/4885S100A4 2175/4885TDP2 3192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.